Veloxis Pharmaceuticals submits NDA to US FDA to market Envarsus for kidney ... pharmabiz.com In the two pivotal trials, Envarsus given once-daily met the primary endpoint of demonstrating comparable efficacy and safety compared to twice-daily tacrolimus (Prograf, Astellas Pharma, Inc.). In the largest study, Study 3002, Envarsus was shown to ... |
